Clinical Trial Update: Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating metronomic oral vinorelbine in combination with anti-PD-L1 and anti-CTLA-4 immunotherapy for patients with advanced solid …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Cervical Cancer
• Head and Neck Cancer
• Prostate Cancer

Drugs mentioned

• Anti-CTLA-4 immunotherapy
• Anti-PD-L1 immunotherapy
• Vinorelbine (Vinorelbine)

Snippet

Sponsor: UNICANCER | Conditions: Advanced Solid Tumours, Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED